表紙
市場調査レポート

Cerulean Pharma, Inc.の製品パイプライン分析

Cerulean Pharma, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321968
出版日 ページ情報 英文 29 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
Cerulean Pharma, Inc.の製品パイプライン分析 Cerulean Pharma, Inc. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 29 Pages
概要

Cerulean Pharma, Inc.は米国に本社を置くバイオ製薬企業で、癌、心血管系疾患、自己免疫および炎症疾患の分野でナノテクノロジーをベースとした治療薬の設計開発を行っています。ナノ粒子の内部に有効成分を化学的に複合させることにより、新規の化学成分を組成し特許を保有しています。

当レポートでは、Cerulean Pharma, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Cerulean Pharma, Inc. の基本情報

  • Cerulean Pharma, Inc. の概要
  • 主要情報
  • 企業情報

Cerulean Pharma, Inc. :R&Dの概要

  • 主な治療範囲

Cerulean Pharma, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Cerulean Pharma, Inc. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Cerulean Pharma, Inc. :薬剤プロファイル

  • CRLX-101
  • docetaxel nanoparticles
  • RNAi Oligonucleotide for Breast Cancer

Cerulean Pharma, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Cerulean Pharma, Inc. :最新のパイプライン情報

Cerulean Pharma, Inc. :開発休止中のプロジェクト

Cerulean Pharma, Inc. :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07543CDB

Summary

Global Markets Direct's, 'Cerulean Pharma, Inc. - Product Pipeline Review - 2015', provides an overview of the Cerulean Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cerulean Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cerulean Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cerulean Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cerulean Pharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate Cerulean Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cerulean Pharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cerulean Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cerulean Pharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cerulean Pharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cerulean Pharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cerulean Pharma, Inc. Snapshot
    • Cerulean Pharma, Inc. Overview
    • Key Information
    • Key Facts
  • Cerulean Pharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Cerulean Pharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cerulean Pharma, Inc. - Pipeline Products Glance
    • Cerulean Pharma, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Cerulean Pharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Cerulean Pharma, Inc. - Drug Profiles
    • CRLX-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cerulean Pharma, Inc. - Pipeline Analysis
    • Cerulean Pharma, Inc. - Pipeline Products by Target
    • Cerulean Pharma, Inc. - Pipeline Products by Route of Administration
    • Cerulean Pharma, Inc. - Pipeline Products by Molecule Type
    • Cerulean Pharma, Inc. - Pipeline Products by Mechanism of Action
  • Cerulean Pharma, Inc. - Recent Pipeline Updates
  • Cerulean Pharma, Inc. - Dormant Projects
  • Cerulean Pharma, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cerulean Pharma, Inc., Key Information
  • Cerulean Pharma, Inc., Key Facts
  • Cerulean Pharma, Inc. - Pipeline by Indication, 2015
  • Cerulean Pharma, Inc. - Pipeline by Stage of Development, 2015
  • Cerulean Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Cerulean Pharma, Inc. - Phase II, 2015
  • Cerulean Pharma, Inc. - Phase I, 2015
  • Cerulean Pharma, Inc. - Preclinical, 2015
  • Cerulean Pharma, Inc. - Pipeline by Target, 2015
  • Cerulean Pharma, Inc. - Pipeline by Route of Administration, 2015
  • Cerulean Pharma, Inc. - Pipeline by Molecule Type, 2015
  • Cerulean Pharma, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Cerulean Pharma, Inc. - Recent Pipeline Updates, 2015
  • Cerulean Pharma, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Cerulean Pharma, Inc. - Pipeline by Top 10 Indication, 2015
  • Cerulean Pharma, Inc. - Pipeline by Stage of Development, 2015
  • Cerulean Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Cerulean Pharma, Inc. - Pipeline by Top 10 Target, 2015
  • Cerulean Pharma, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Cerulean Pharma, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Cerulean Pharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top